A novel ADC targeting HER2 pathways based on Alteogen's NexMab ADC technology.
ALTEOGEN succeeded in registering the patent for long-acting recombinant Alpha-1 Antitrypsin (A1AT) in US.
The cooperation project between KISSEI and ALTEOGEN has been progressing steadily.
ALTEOGEN (KOSDAQ:196170) is started to be traded in Korean stock market, KOSDAQ on 12th Dec. 2014.
ALTEOGEN's patent for NexP™ fusion technology registered in EU on 3rd Dec 2014.
 1  2  3  4